Grail Inc (GRAL) Stock Price, Quote & News

Company Profile

GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therap...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 833 694 2553

Website: grail.com

Address:

1525 O’Brien Drive, Menlo Park, United States

Monkey7779192 Aug. 18 at 7:43 PM

$GRAL This board is quite. I think it will be heavily judged by fda but well see how the ask the panel to vote.

0 · Reply

justiceforb_85 Aug. 14 at 6:03 PM

$GRAL know the company did not meet the primary endpoint in their NHS trial but the adcom may review the data in a nuanced fashion. Leaning positive here but would be worth an entry if it dips prior to the scheduled committee review.

2 · Reply

TheUnmaker Aug. 13 at 7:11 AM

$TNXP Something big is brewing here. It feels like $GRAL when I was in at $15 - $17. $PFE $JNJ $PG

0 · Reply

TheUnmaker Aug. 10 at 8:18 PM

$TNXP Today confirmed the setup with massive over than average volume. Algos re ready to run higher. We will break $14.15 this week and then looking for demand over $16. $PFE $JNJ $GRAL $SLS

1 · Reply

CarverX Aug. 10 at 5:10 PM

$WGS $TEM $GRAL 🚀🚀🚀

0 · Reply

fda_tracker Aug. 10 at 3:42 PM

$GRAL New FDA AdCom 2026-09-23 GRAIL, Inc. Link:https://www.fda.gov/advisory-committees/advisory-committee-calendar/september-23-2026-molecular-and-clinical-genetics-panel-medical-devices-advisory-committee-meeting Calendar:http://www.fdatracker.com/fda-calendar/

0 · Reply

TheUnmaker Aug. 10 at 2:08 PM

$TNXP Break $14.15 and we go back over $16 this week. $PFE $SLS $JNJ $GRAL

1 · Reply

TheUnmaker Aug. 10 at 2:25 AM

$TNXP this will run like $GRAL did.

0 · Reply

Chipmonk1 Aug. 9 at 8:10 PM

$GRAL think FDA going to let it go

0 · Reply

dario2580 Aug. 9 at 7:36 PM

$GRAL Strong revenue growth📈

0 · Reply

GRAIL Transcript: Canaccord Genuity's 46th Annual Growth Conference

Aug 7, 2026, 11:26 AM EDT - 11 days ago

US FDA to hold advisory meeting to review Grail's multi-cancer test

2026-08-07T15:10:45.000Z - 11 days ago

Grail announces FDA advisory committee meeting to review Galleri test PMA

Aug 7, 2026, 11:05 AM EDT - 11 days ago

GRAIL Announces FDA Advisory Committee Meeting to Review Premarket Approval Application for the Galleri® Multi-Cancer Early Detection Test

Aug 5, 2026, 4:30 PM EDT - 13 days ago

GRAIL Earnings Call Transcript: Q2 2026

Aug 5, 2026, 4:30 PM EDT - 13 days ago

GRAIL Earnings release: Q2 2026

Aug 5, 2026, 4:30 PM EDT - 13 days ago

GRAIL Quarterly report: Q2 2026

2026-08-05T20:10:47.000Z - 13 days ago

Grail reports Q2 EPS ($2.56), consensus ($2.43)

Aug 5, 2026, 4:02 PM EDT - 13 days ago

GRAIL Reports Second Quarter 2026 Financial Results

Jul 30, 2026, 4:01 PM EDT - 19 days ago

GRAIL to Present at the Canaccord Genuity 46th Annual Growth Conference

Jul 30, 2026, 10:07 AM EDT - 19 days ago

SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of August 4, 2026 in Grail, Inc. Lawsuit - GRAL

Jul 29, 2026, 4:01 PM EDT - 20 days ago

GRAIL to Announce Second Quarter 2026 Financial Results

Jul 24, 2026, 6:36 AM EDT - 26 days ago

$GRAL Fraud Notification: GRAIL, Inc. Sued for Fraud Over Misrepresentations about its Trial Results – Investors Notified to Contact BFA Law

2026-07-16T13:11:41.000Z - 4 weeks ago

Grail’s Gallery cancer detection test adopted by Priority Health

Jul 16, 2026, 9:00 AM EDT - 4 weeks ago

Priority Health Collaborates With GRAIL as the First Michigan Health Plan to Offer the Galleri® Multi-Cancer Early Detection Blood Test to Employer Plans

2026-07-15T12:50:43.000Z - 4 weeks ago

Grail price target raised to $88 from $69 at TD Cowen

2026-07-15T11:32:38.000Z - 5 weeks ago

Grail price target raised to $65 from $58 at Mizuho

Jul 6, 2026, 6:48 AM EDT - 6 weeks ago

$GRAL Fraud Notification: GRAIL, Inc. Sued for Securities Fraud After Trial Results Spark a 50% Stock Drop – Investors Notified to Contact BFA Law by August 4

Jul 2, 2026, 9:37 AM EDT - 6 weeks ago

GRAIL, Inc. (GRAL) Securities Fraud: Contact Berger Montague to Discuss Your Rights

Jul 1, 2026, 6:21 PM EDT - 6 weeks ago

GRAL Investors Have Rights – If You Lost Money Investing in Grail, Inc. Contact Robbins LLP for Information About Recovering Your Losses

Jun 25, 2026, 9:00 AM EDT - 7 weeks ago

GRAIL Completes $110 Million Equity Financing With Samsung Entities

Jun 18, 2026, 4:00 PM EDT - 2 months ago

GRAIL Transcript: AGM 2026

Jun 12, 2026, 4:07 PM EDT - 2 months ago

GRAL Breaking News: GRAIL, Inc. Sued for Securities Fraud after Trial Results Lead to 50% Stock Drop – Investors Notified to Contact BFA Law

Jun 10, 2026, 9:47 AM EDT - 2 months ago

GRAIL, INC. (GRAL) INVESTOR ALERT Investors With Large Losses in GRAIL, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Jun 9, 2026, 11:20 AM EDT - 2 months ago

GRAIL Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

2026-06-05T08:40:29.000Z - 2 months ago

Grail initiated with a Neutral at Goldman Sachs

Jun 3, 2026, 7:35 AM EDT - 2 months ago

GRAIL Transcript: Jefferies Global Healthcare Conference 2026

2026-06-01T20:52:46.000Z - 2 months ago

Grail assumed with a Peer Perform at Wolfe Research

2026-06-01T16:35:00.000Z - 2 months ago

Grail falls -15.6%

2026-06-01T16:10:37.000Z - 2 months ago

Grail falls -18.4%

May 31, 2026, 7:00 PM EDT - 2 months ago

GRAIL Transcript: Study result

May 31, 2026, 7:00 PM EDT - 2 months ago

GRAIL Press release: Study result

May 31, 2026, 7:00 PM EDT - 2 months ago

GRAIL Slides: Study result

2026-05-31T21:43:31.000Z - 2 months ago

Grail presents ‘positive’ performance, safety results from Pathfinder 2 study

2026-05-31T21:36:48.000Z - 2 months ago

Grail reports results from NHS-Galleri trial in presentation at ASCO meeting

May 31, 2026, 8:00 AM EDT - 2 months ago

GRAIL Presents PATHFINDER 2 Results of More Than 35,000 Participants Showing the Galleri® Test Substantially Increased Cancer Detection With Robust Performance and Favorable Safety at 2026 ASCO Annual Meeting

May 30, 2026, 8:00 AM EDT - 2 months ago

GRAIL Reports Full Results From NHS-Galleri Trial Demonstrating Substantial Reduction in Stage IV Cancer Diagnoses at 2026 ASCO Annual Meeting

May 27, 2026, 4:01 PM EDT - 2 months ago

GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

May 26, 2026, 4:01 PM EDT - 3 months ago

GRAIL to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

May 21, 2026, 4:01 PM EDT - 3 months ago

GRAIL to Present at the 2026 Jefferies Global Healthcare Conference

May 12, 2026, 11:40 AM EDT - 3 months ago

GRAIL Transcript: Bank of America Global Healthcare Conference 2026

2026-05-07T09:18:38.000Z - 3 months ago

Grail price target lowered to $70 from $82 at Baird

2026-05-07T07:52:29.000Z - 3 months ago

Grail price target raised to $56 from $54 at Piper Sandler

2026-05-07T05:21:56.000Z - 3 months ago

Grail price target raised to $69 from $65 at TD Cowen

May 6, 2026, 10:00 AM EDT - 3 months ago

Zaya Younan Unveils the Scientific Holy Grail of Cigar Smoking

2026-05-05T20:33:50.000Z - 3 months ago

Grail reports Q1 EPS ($2.29), consensus ($1.96)

May 5, 2026, 4:30 PM EDT - 3 months ago

GRAIL Earnings Call Transcript: Q1 2026

May 5, 2026, 4:30 PM EDT - 3 months ago

GRAIL Earnings release: Q1 2026

May 5, 2026, 4:30 PM EDT - 3 months ago

GRAIL Quarterly report: Q1 2026

May 5, 2026, 4:01 PM EDT - 3 months ago

GRAIL Reports First Quarter 2026 Financial Results

Apr 30, 2026, 4:01 PM EDT - 3 months ago

GRAIL to Present at the BofA Securities 2026 Health Care Conference

Apr 28, 2026, 8:00 AM EDT - 4 months ago

GRAIL Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 4 months ago

GRAIL Proxy statement: Proxy filing

Apr 22, 2026, 4:01 PM EDT - 4 months ago

GRAIL to Announce First Quarter 2026 Financial Results

Apr 21, 2026, 4:53 PM EDT - 4 months ago

GRAIL to Present New Data From NHS-Galleri and PATHFINDER 2 at 2026 ASCO Annual Meeting

2026-04-10T09:55:12.000Z - 4 months ago

Grail initiated with a Neutral at Mizuho

2026-04-10T08:45:11.000Z - 4 months ago

Grail initiated with a Neutral at Piper Sandler

2026-04-07T20:05:13.000Z - 4 months ago

Grail announces collaboration with Epic to bring Galleri test to EHR platforms

Apr 7, 2026, 4:01 PM EDT - 4 months ago

GRAIL Announces Integration of the Galleri® Test into Epic Electronic Health Record Platform to Expand Access Nationwide

2026-04-01T17:15:43.000Z - 4 months ago

Grail, Superpower partner to expand early cancer detection

Apr 1, 2026, 1:09 PM EDT - 4 months ago

Cancer Is Striking Earlier -- Superpower and GRAIL Are Partnering to Expand Early Detection

2026-03-30T11:54:36.000Z - 5 months ago

Grail price target lowered to $75 from $130 at Guggenheim

Mar 12, 2026, 6:13 PM EDT - 5 months ago

Grail CEO Bob Ragusa to retire, Josh Ofman named successor

Mar 12, 2026, 4:30 PM EDT - 5 months ago

GRAIL Announces Retirement of CEO Bob Ragusa and Appointment of Josh Ofman, MD, MSHS, as Successor

Mar 5, 2026, 9:00 AM EST - 5 months ago

Levi & Korskinsky, LLP: Grail (GRAL) Guided to 2030 Cash Runway While Key Trial Risk Went Unaddressed

Mar 3, 2026, 10:30 AM EST - 6 months ago

GRAIL Transcript: TD Cowen 46th Annual Health Care Conference

Feb 24, 2026, 4:02 PM EST - 6 months ago

GRAIL to Present at the TD Cowen 46th Annual Health Care Conference

Feb 23, 2026, 9:06 AM EST - 6 months ago

'Holy Grail' Honus Wagner card sells for over $5M as family auctions it from grandfather's collection

Feb 20, 2026, 4:26 PM EST - 6 months ago

This once-hot cancer-detection company's stock got cut in half after a failed trial

Feb 20, 2026, 8:35 AM EST - 6 months ago

Grail shares plunge after major cancer screening trial misses main goal

Feb 20, 2026, 4:06 AM EST - 6 months ago

Grail Stock Plunges 50% After Earnings. But It's These Test Results That Are to Blame.

Feb 19, 2026, 9:27 PM EST - 6 months ago

Grail Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Feb 19, 2026, 5:00 PM EST - 6 months ago

GRAIL Earnings Call Transcript: Q4 2025

Feb 19, 2026, 5:00 PM EST - 6 months ago

GRAIL Annual report: Q4 2025

Feb 19, 2026, 5:00 PM EST - 6 months ago

GRAIL Earnings release: Q4 2025

Feb 19, 2026, 4:02 PM EST - 6 months ago

GRAIL Reports Fourth Quarter and Full Year 2025 Financial Results

Feb 19, 2026, 4:01 PM EST - 6 months ago

Landmark NHS-Galleri Trial Demonstrates a Substantial Reduction in Stage IV Cancer Diagnoses, Increased Stage I and II Detection of Deadly Cancers, and Four-Fold Higher Cancer Detection Rate

Feb 16, 2026, 9:00 AM EST - 6 months ago

GRAIL to Announce Fourth Quarter and Full Year 2025 Financial Results

Monkey7779192 Aug. 18 at 7:43 PM

$GRAL This board is quite. I think it will be heavily judged by fda but well see how the ask the panel to vote.

0 · Reply

justiceforb_85 Aug. 14 at 6:03 PM

2 · Reply

TheUnmaker Aug. 13 at 7:11 AM

$TNXP Something big is brewing here. It feels like $GRAL when I was in at $15 - $17. $PFE $JNJ $PG

0 · Reply

TheUnmaker Aug. 10 at 8:18 PM

$TNXP Today confirmed the setup with massive over than average volume. Algos re ready to run higher. We will break $14.15 this week and then looking for demand over $16. $PFE $JNJ $GRAL $SLS

1 · Reply

CarverX Aug. 10 at 5:10 PM

$WGS $TEM $GRAL 🚀🚀🚀

0 · Reply

fda_tracker Aug. 10 at 3:42 PM

0 · Reply

TheUnmaker Aug. 10 at 2:08 PM

$TNXP Break $14.15 and we go back over $16 this week. $PFE $SLS $JNJ $GRAL

1 · Reply

TheUnmaker Aug. 10 at 2:25 AM

$TNXP this will run like $GRAL did.

0 · Reply

Chipmonk1 Aug. 9 at 8:10 PM

$GRAL think FDA going to let it go

0 · Reply

dario2580 Aug. 9 at 7:36 PM

$GRAL Strong revenue growth📈

0 · Reply

JFDI Aug. 9 at 3:27 PM

$GRAL

0 · Reply

Merlintrader Aug. 9 at 3:44 AM

$GRAL — Galleri at the FDA: a missed endpoint, a Stage IV signal—and a test that could redraw cancer screening https://www.merlintrader.com/gral-galleri-fda-adcom-cancer-blood-test/

0 · Reply

STACKD0E Aug. 7 at 4:18 PM

$GD $GRAL 👁️

0 · Reply

notreload_ai Aug. 7 at 3:53 PM

$GRAL Galleri multi-cancer blood test heads to an FDA advisory meeting on Sept. 23 as the company seeks full approval for early cancer detection. https://notreload.xyz/xy/fda-to-review-grail-galleri-cancer-test-on-sept-23/

0 · Reply

gobio Aug. 7 at 3:10 PM

$GRAL MENLO PARK, Calif. , Aug. 7, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that the U.S. Food and Drug Administration's ( FDA ) Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee is scheduled to meet on Sept. 23, 2026 to review the Premarket Approval (PMA) application for the Galleri® multi-cancer early detection (MCED) blood test. The Galleri test is designed to detect cancer-specific methylation patterns shared by many types of cancer before symptoms appear, including cancers that do not have recommended screening today. When a cancer signal is detected, Galleri is designed to predict the cancer signal origin with high accuracy to help guide diagnostic evaluation. The test is intended to be used in addition to, and not as a replacement for, guideline-recommended screenings.

0 · Reply